Neurol Ther. 2016 Dec;5(2):193-201. doi: 10.1007/s40120-016-0051-7. Epub 2016 Sep 13.

Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study.

Neurology and therapy

Ralf A Linker, Guillaume Wendt

PMID: 27624575 PMCID: PMC5130918 DOI: 10.1007/s40120-016-0051-7

Abstract

INTRODUCTION: Fingolimod was the first oral therapy approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Due to its action on cardiac sphingosine 1-phosphate receptors, fingolimod is leading to a transient decrease in heart rate (HR) and the occurrence of rare and asymptomatic self-limited atrioventricular (AV) blocks. This German non-interventional clinical study aimed to assess the cardiac safety profile in RRMS patients during at least 6 h after the initial treatment or restart after interruption of fingolimod in real-world settings.

METHODS: The GoCARD study (German National Health Authorities, BfArM, CFTY720DDE18, NIS334) was a prospective, multi-center non-interventional study which was conducted in neurological and other medical practices or hospitals, qualified to routinely assess electrocardiogram (ECG) findings. Data were collected through interviews, clinical evaluations (notably ECGs), and laboratory tests. Medical history, vital signs, and a 12-lead ECG were assessed before fingolimod administration. After the first dose, a 6 h ECG was performed and vital signs (blood pressure and HR) were measured hourly. The occurrence of bradycardia (HR ≤45 beats per minute [BPM]), AV blocks (2nd degree Mobitz type I or higher), and corrected QT interval (QTc) intervals was also documented.

RESULTS: More than 95% of physicians adhered to the cardiac monitoring recommendations. The observation of 217 patients in 42 study centers showed that while 35.9% of the patients had any cardiac risk profile, none of them experienced a bradycardia during the 6 h post-dose observation. Overall, only 1.8% of all patients displayed bradycardia (HR ≤45 BPM) during 6 h after treatment initiation. Moreover, in this cohort, none of the patients showed a new or persistent onset AV block (2nd degree Mobitz type I or higher) or QTc ≥500 ms.

CONCLUSION: Altogether, these data confirm that the first-dose observation after fingolimod initiation is usually uneventful (even in patients with pre-existing cardiovascular risk factors of this cohort) and that the rarely observed events remained asymptomatic and self-limited.

FUNDING: Novartis Pharma GmbH, Nürnberg, Germany.

Keywords: Disease-modifying treatment; Fingolimod; Multiple sclerosis; Real-world evidence

References

1. BMC Pharmacol Toxicol. 2015 Apr 01;16:7 - PubMed
2. Drug Healthc Patient Saf. 2015 Dec 11;7:157-67 - PubMed
3. Mult Scler Relat Disord. 2014 Sep;3(5):629-38 - PubMed
4. N Engl J Med. 2010 Feb 4;362(5):387-401 - PubMed
5. Adv Ther. 2015 Jul;32(7):636 - PubMed
6. J Clin Pharmacol. 2015 Oct;55(10):1131-6 - PubMed
7. Mult Scler Relat Disord. 2014 Jul;3(4):494-504 - PubMed
8. BMC Neurol. 2014 Apr 01;14:65 - PubMed
9. J Neurol Sci. 2012 Dec 15;323(1-2):167-72 - PubMed
10. Neurology. 1983 Nov;33(11):1444-52 - PubMed
11. J Neurol. 2014 Feb;261(2):267-76 - PubMed
12. J Neuroimmunol. 2015 Dec 15;289:93-7 - PubMed
13. Annu Rev Immunol. 2005;23:683-747 - PubMed
14. N Engl J Med. 2010 Feb 4;362(5):402-15 - PubMed
15. Adv Ther. 2015 Jul;32(7):626-35 - PubMed
16. J Mol Cell Cardiol. 2010 Feb;48(2):406-14 - PubMed

Publication Types

• Journal Article